Bacillus subtilis and Enterococcus faecium enteric-coated capsules combined with mesalazine for treatment of patients with ulcerative colitis: Efficacy and impact on serum levels of SOD, MDA, interleukins, and TNF-α

World Chinese Journal of Digestology

Volumn 26, Issue 12, 2018, Pages 748-754

  Shi, Xiao Hong ^a   Tan, Feng Ping ^a   Jiang, Wen Hua ^a  

^a Anji County People s Hospital of Huzhou City   (China)

Author keywords

Bacillus subtilis; Enteric coated capsules; Inflammatory factor; Mesalazine; Oxidative stress; Ulcerative colitis

Indexed keywords

CYCLOOXYGENASE 2; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MALONALDEHYDE; MESALAZINE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR;

ABDOMINAL PAIN; ARTICLE; BACILLUS SUBTILIS; CLINICAL FEATURE; CONTROLLED STUDY; DIARRHEA; DRUG DOSAGE FORM; DRUG EFFICACY; ENTERIC COATED CAPSULE; ENTEROCOCCUS FAECIUM; HUMAN; MAJOR CLINICAL STUDY; MUCUS; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; ULCERATIVE COLITIS;

EID: 85046083115     PISSN: 10093079     EISSN: None     Source Type: Journal    
DOI: 10.11569/wcjd.v26.i12.748     Document Type: Article

References (6)

1. Zhang HL, Li WS, Xu DN, Zheng WW, Liu Y, Chen J, Qiu ZB, Dorfman RG, Zhang J, Liu J. Mucosa-reparing and microbiota-balancing therapeutic effect of Bacillus subtilis alleviates dextrate sulfate sodium-induced ulcerative colitis in mice. Exp Ther Med 2016; 12: 2554-2562 [DOI: 10.3892/etm.2016.3686]
2. Zhu Z, Shu X, Long S, Jiang X, Lu N, Zhu X, Liao W. Ulcerative colitis followed by the development of typical intestinal Behçet disease: A case report. Medicine (Baltimore) 2018; 97: e9882 [DOI:10.1097/MD.0000000000009882]
3. Dignass A, Schnabel R, Romatowski J, Pavlenko V, Dorofeyev A, Derova J, Jonaitis L, Dilger K, Nacak T, Greinwald R; International SAT-25 Study Group. Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a doubleblind, multicentre, randomised trial. United European Gastroenterol J 2018; 6: 138-147 [DOI:10.1177/2050640617703842, ]
4. Seo HI, Lee HJ, Han KH. Hyperbaric oxygen therapy for pyoderma gangrenosum associated with ulcerative colitis. Intest Res 2018; 16: 155-157 [DOI:10.5217/ir.2018.16.1.155]
5. Park SW, Jee SR, Kim JH, Lee SH, Hwang JW, Jang JG, Lee DW, Seol SY. Duodenal amyloidosis secondary to ulcerative colitis. Intest Res 2018; 16: 151-154 [DOI: 10.5217/ir.2018.16.1.151]
6. Yarlas A, D’Haens G, Willian MK, Teynor M. Health-Related Quality of Life and Work-Related Outcomes for Patients With Mild-to-Moderate Ulcerative Colitis and Remission Status Following Short-Term and Long-Term Treatment With Multimatrix Mesalamine: A Prospective, Open-Label Study. Inflamm Bowel Dis 2018; 24: 450-463 [DOI: 10.1093/ibd/izx041]